Join Growin Stock Community!

Cingulate inc.CING.US Overview

US StockHealthcare
(No presentation for CING)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CING AI Insights

CING Overall Performance

CING AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CING Recent Performance

4.86%

Cingulate inc.

0.05%

Avg of Sector

-0.31%

S&P500

CING PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CING Key Information

CING Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CING Profile

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Price of CING

CING FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CING Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.94
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
13.91
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.94
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
13.91
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is CING's latest earnings report released?

    The most recent financial report for Cingulate inc. (CING) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CING's short-term business performance and financial health. For the latest updates on CING's earnings releases, visit this page regularly.

  • How much debt does CING have?

    As of the end of the reporting period, Cingulate inc. (CING) had total debt of 4.58M, with a debt ratio of 0.44. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CING have?

    At the end of the period, Cingulate inc. (CING) held Total Cash and Cash Equivalents of 6.12M, accounting for 0.58 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is CING's EPS continuing to grow?

    According to the past four quarterly reports, Cingulate inc. (CING)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.35. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CING?

    Cingulate inc. (CING)'s Free Cash Flow (FCF) for the period is -4.24M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 13.4% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of CING?

    The latest valuation data shows Cingulate inc. (CING) has a Price-To-Earnings (PE) ratio of -1.02 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.